Synairgen (LON:SNG) Stock Crosses Below 200 Day Moving Average of $14.55
Synairgen (LON:SNG) Stock Crosses Below 200 Day Moving Average of $14.55
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.Synairgen plc (LON:SNG – Get Rating)'s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 14.55 ($0.18) and traded as low as GBX 12.02 ($0.15). Synairgen shares last traded at GBX 13.22 ($0.16), with a volume of 269,782 shares.
在周四的交易中，Synairgen plc（LON: SNG — 获取评级）的股价跌破了两百天移动平均线。该股的两百天移动平均线为GBX 14.55美元（0.18美元），交易价格低至GBX 12.02（0.15美元）。Synairgen股票最后一次交易价格为GBX 13.22美元（0.16美元），成交量为269,782股。
Synairgen Trading Down 5.4 %
Synairgen 交易量下跌5.4％
The company has a market capitalization of £25.17 million, a PE ratio of -52.08 and a beta of -2.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.35 and a quick ratio of 6.35. The firm's 50 day moving average is GBX 10.73 and its 200 day moving average is GBX 14.53.
该公司的市值为2517万英镑，市盈率为-52.08，beta值为-2.29。该公司的债务与权益比率为0.09，流动比率为6.35，速动比率为6.35。该公司的50天移动平均线为GBX 10.73，其200天移动平均线为GBX 14.53。
Synairgen Company Profile
Synairgen 公司简介
(Get Rating)
（获取评分）
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc 发现并开发了治疗呼吸系统疾病的药物。它开发了 SNG001，一种用于治疗 COVID-19 的吸入性干扰素 β；用于治疗普通感冒和流感引起的哮喘的吸入性β干扰素（ifn-β）；正在进行治疗或预防慢性阻塞性肺疾病的 IFN-β；以及用于治疗特发性肺纤维化 (IPF) 疾病的 LOXL2 抑制剂。
Featured Articles
精选文章
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation's Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- MarketBeat 周回顾 — 4 月 17 日 — 4 月 21 日
- 2 只工业实力股息股票正在融化
- 宝洁将创下新高
- AutoNation的计划让分析师待在身边
- Netflix 增加回购：它能否在 2023 年完成逆转？
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Synairgen 每日的新闻和收视率 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Synairgen及相关公司最新新闻和分析师评级的简明每日摘要。
